SEARCH

SEARCH BY CITATION

References

  • 1
    Runyon BA. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009;49:2087-2107.
  • 2
    Runyon BA, Montano AA, Akriviadis EA, Antillon MR, Irving MA, McHutchison JG. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med 1992;117:215-220.
  • 3
    Henriksen JH, Horn T, Christoffersen P. The blood-lymph barrier in the liver. A review based on morphological and functional concepts of normal and cirrhotic liver. Liver 1984;4:221-232.
  • 4
    Christou L, Economou M, Economou G, Kolettis M, Tsianos EV. Characteristics of ascitic fluid in cardiac ascites. Scand J Gastroenterol 2007;42:1102-1105.
  • 5
    Stevenson LW, Perloff JK. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA 1989;261:884-888.
  • 6
    Remes J, Miettinen H, Reunanen A, Pyorala K. Validity of clinical diagnosis of heart failure in primary health care. Eur Heart J 1991;12:315-321.
  • 7
    de Lemos JA, McGuirre DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003;362:316-322.
  • 8
    Suttner SW, Boldt J. Natriuretic peptide system: physiology and clinical utility. Curr Opin Crit Care 2004;10:336-341.
  • 9
    Maisel A, Krishnaswamy P, Nowak RM, McCord J, Hollander J, Duc P, et al. Rapid Measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-167.
  • 10
    Maisel AS, McCord J, Nowak RM, Hollander JE, Wu AH, Duc P, et al. Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. J Am Coll Cardiol 2003;41:2010-2017.
  • 11
    Maisel A, Mueller C, Adams K, Jr., Anker SD, Aspromonte N, Cleland JGF, et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008;10:824-839.
  • 12
    Mueller C, Scholer A, Laule-Kilian K, Martina B, Schindler C, Buser P, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. New Engl J Med 2004;350:647-654.
  • 13
    Zardi EM, Abbate A, Zardi DM, Dobrina A, Margiotta D, Van Tassell BW, et al. Cirrhotic cardiomyopathy. J Am Coll Cardiol 2010;56:539-549.
  • 14
    Yildiz R, Yildirim B, Karincaoglu M, Harputluoglu M, Hilmioglu F. Brain natriuretic peptide and severity of disease in non-alcoholic cirrhotic patients. J Gastroenterol Hepatol 2005;20:1115-1120.
  • 15
    Henriksen JH, Gøtze JP, Fuglsang S, Christensen E, Bendtsen F, Møller S. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut 2003;52:1511-1517.
  • 16
    Porcel JM, Martínez-Alonso M, Cao G, Bielsa S, Sopena A, Esquerda A. Biomarkers of heart failure in pleural fluid. Chest 2009;136:671-677.
  • 17
    Kolditz M, Halank M, Schiemanck CS, Schmeisser A, Höffken G. High diagnostic accuracy of NT-proBNP for cardiac origin of pleural effusions. Eur Respir J 2006;28:144-150.
  • 18
    Tomcsányi J, Nagy E, Somlói M, Moldvay J, Bezzegh A, Bózsik B, et al. NT-brain natriuretic peptide levels in pleural fluid distinguish between pleural transudates and exudates. Eur J Heart Fail 2004;6:753-756.
  • 19
    Jessup M, Abraham W, Casey DE, Feldman A, Francis GS, Ganiats TG, et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119:1977-2016.
  • 20
    Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2008;29:2388-2442.
  • 21
    McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure. The Framingham Study. N Engl J Med 1971;285:1441-1446.
  • 22
    Carlson KJ, Lee DC, Goroll AH, Leahy M, Johnson RA. An analysis of physicians' reasons for prescribing long-term digitalis therapy in outpatients. J Chronic Dis 1985;38:733-739.
  • 23
    Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440-1463.
  • 24
    Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009;22:107-212.
  • 25
    The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th ed. Boston, MA: Little, Brown & Co; 1994:253-256.
  • 26
    Wheeldon NM, MacDonald TM, Flucker CJ, McKendrick AD, McDevitt DG, Struthers AD. Echocardiography in chronic heart failure in the community. Q J Med 1993;86:17-23.
  • 27
    Davis RC, Hobbs FD, Kenkre JE, Roalfe AK, Hare R, Lancashire RJ, et al. Prevalence of heart failure in high risk groups: community based epidemiological study. BMJ 2002;325:1156.
  • 28
    Mant J, Doust J, Roalfe A, Barton P, Cowie MR, Glasziou P, et al. Systematic review and individual patients data meta-analysis of diagnosis of heart failure, with modeling of implications of different diagnostic strategies in primary care. Health Technol Assess 2009;13:1-207.
  • 29
    Mant J, Al-Mohammad A, Swain S, Laramee P. Management of chronic heart failure in adults: synopsis of the National Institute for Health and Clinical Excellence. Ann Intern Med 2011;155:252-259.
  • 30
    Garcia-Tsao G. Ascites. In: Boyer TD, Manns MP, Sanyal AJ, eds. Zakim and Boyer's Hepatology. A Textbook of Liver Disease. 6th ed. Philadelphia, PA: Elsevier Saunders; 2012:283-295.
  • 31
    Rider H, Meyer zum Büschenfelde KH, Ramadori G. Functional spectrum of sinusoidal endothelial liver cells: filtration, endocytosis, synthetic capacities, and intercellular communication. J Hepatol 1992;15:237-250.
  • 32
    Wisse E, De Zanger RB, Charels K, Van Der Smissen P, McCuskey RS. The liver sieve: considerations concerning the structure and function of endothelial fenestrae, the sinusoidal wall and the space of Disse. Hepatology 1985;5:683-692.
  • 33
    Fraser R, Dobbs BR, Rogers GW. Lipoproteins and the liver sieve: the role of the fenestrated sinusoidal endothelium in lipoprotein metabolism, atherosclerosis, and cirrhosis. Hepatology 1995;21:863-874.
  • 34
    Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann Intern Med 2003;138:W1-W12.
  • 35
    Sheer TA, Joo E, Runyon BA. Usefulness of serum N-terminal-ProBNP in distinguishing ascites due to cirrhosis from ascites due to heart failure. J Clin Gastroenterol 2010;44:e23-e26.
  • 36
    Manzano-Fernández S, Januzzi JL, Boronat-García M, Pastor P, Albaladejo-Otón MD, Garrido IP, et al. Impact of kidney dysfunction on plasma and urinary N-terminal pro-B-type natriuretic peptide in patients with acute heart failure. Congest Heart Fail 2010;16:214-220.
  • 37
    McCullough PA, Duc P, Omland T, McCord J, Nowak RM, Hollander JE, et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis 2003;41:571-579.
  • 38
    Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol 2007;50:2357-2368.